PEN Stock Overview
Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 4/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for PEN from our risk checks.
Penumbra, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$262.43 |
| 52 Week High | US$348.67 |
| 52 Week Low | US$144.76 |
| Beta | 0.54 |
| 1 Month Change | 5.52% |
| 3 Month Change | -22.81% |
| 1 Year Change | 41.08% |
| 3 Year Change | 28.35% |
| 5 Year Change | 70.13% |
| Change since IPO | 535.42% |
Recent News & Updates
Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy
Sep 01A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Aug 15
Recent updates
Penumbra: Consolidation Does Nothing To Change Long-Term Thesis, Reiterate Buy
Sep 01A Look At The Intrinsic Value Of Penumbra, Inc. (NYSE:PEN)
Aug 15Penumbra (NYSE:PEN) Has Some Way To Go To Become A Multi-Bagger
Jun 28Penumbra: Future Upside Drivers In Fundamental, Sentimental And Valuation Factors
Jun 22Getting In Cheap On Penumbra, Inc. (NYSE:PEN) Might Be Difficult
Jun 02We're Not Worried About Penumbra's (NYSE:PEN) Cash Burn
Apr 01Penumbra Non-GAAP EPS of $0.16 beats by $0.01, revenue of $221.22M beats by $4.19M
Feb 23Penumbra Riding Higher On Upcoming Launches And Rerating
Jan 12Penumbra: Today's Best Medical Equipment Nearby Cap-Gain Buy
Nov 03Penumbra cut to Neutral at Citi on macro concerns
Oct 05Penumbra, Asahi team up to bring blood clot removing device Indigo to Japan
Sep 22Penumbra stock rises ~11% after announcing European launch of catheters for stroke care
Sep 07Sector Rerating Has Cast A Shadow Over Penumbra
Aug 18Penumbra gains as RBC initiates at Outperform with 59% upside
Jul 18Penumbra: Multiple Downside Targets, Rescued By Long-Term Value Proposition
Jun 10Penumbra A Little Beaten Down Despite Strong Growth Opportunities
Mar 01Returns On Capital Are Showing Encouraging Signs At Penumbra (NYSE:PEN)
Dec 01Shareholders Can Be Confident That Penumbra's (NYSE:PEN) Earnings Are High Quality
Aug 17Returns On Capital Are Showing Encouraging Signs At Penumbra (NYSE:PEN)
Aug 11Penumbra: Short Thesis Did Not Hold, Core Business Remains Strong
Jul 24Shareholders Will Probably Not Have Any Issues With Penumbra, Inc.'s (NYSE:PEN) CEO Compensation
May 27Penumbra EPS beats by $0.18, beats on revenue
May 04Shareholder Returns
| PEN | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -6.0% | -2.0% | -1.5% |
| 1Y | 41.1% | 5.9% | 13.8% |
Return vs Industry: PEN exceeded the US Medical Equipment industry which returned 4.5% over the past year.
Return vs Market: PEN exceeded the US Market which returned 12.9% over the past year.
Price Volatility
| PEN volatility | |
|---|---|
| PEN Average Weekly Movement | 5.0% |
| Medical Equipment Industry Average Movement | 7.2% |
| Market Average Movement | 5.6% |
| 10% most volatile stocks in US Market | 14.3% |
| 10% least volatile stocks in US Market | 2.5% |
Stable Share Price: PEN is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.
Volatility Over Time: PEN's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 3,900 | Adam Elsesser | https://www.penumbrainc.com |
Penumbra, Inc., together with its subsidiairies, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers aspiration based thrombectomy systems and accessory devices, including revascularization device for mechanical thrombectomy, such as Penumbra System under the Penumbra RED, JET, ACE, 3D Revascularization Device, and Penumbra ENGINE brands, as well as components and accessories; neurovascular embolization coiling systems to treat patients with various sizes of aneurysms and other neurovascular lesions under the Penumbra Coil 400, POD400, PAC400, and Penumbra SMART Coil brand names; and neurovascular access systems designed to provide intracranial access for use in a range of neurovascular therapies under the Neuron, Neuron MAX, Select, BENCHMARK, BMX96, DDC, SENDit, and PX SLIM brands. It also provides neurosurgical aspiration tools for the removal of tissue and fluids under the Artemis Neuro Evacuation Device brand; aspiration-based thrombectomy systems for vascular applications under the Indigo System, Lightning, and CAT RX brand; and detachable embolic coil systems for peripheral embolization under the Ruby Coil and Ruby LP brand names.
Penumbra, Inc. Fundamentals Summary
| PEN fundamental statistics | |
|---|---|
| Market Cap | US$10.09b |
| Earnings (TTM) | US$29.13m |
| Revenue (TTM) | US$937.79m |
346.3x
P/E Ratio10.8x
P/S RatioIs PEN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PEN income statement (TTM) | |
|---|---|
| Revenue | US$937.79m |
| Cost of Revenue | US$346.10m |
| Gross Profit | US$591.69m |
| Other Expenses | US$562.56m |
| Earnings | US$29.13m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | 0.76 |
| Gross Margin | 63.09% |
| Net Profit Margin | 3.11% |
| Debt/Equity Ratio | 0% |
How did PEN perform over the long term?
See historical performance and comparison